{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:04:35Z","timestamp":1790395475350,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2008,4,22]],"date-time":"2008-04-22T00:00:00Z","timestamp":1208822400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1038\/ncpneph0806","type":"journal-article","created":{"date-parts":[[2008,4,22]],"date-time":"2008-04-22T18:50:25Z","timestamp":1208890225000},"page":"327-336","source":"Crossref","is-referenced-by-count":70,"title":["Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults"],"prefix":"10.1038","volume":"4","author":[{"given":"Alberto","family":"Ortiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o P","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry M","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Waldek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G","family":"Warnock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,4,22]]},"reference":[{"key":"BFncpneph0806_CR1","first-page":"3733","volume-title":"The Metabolic Bases of Inherited Disease","author":"R Desnick","year":"2001","unstructured":"Desnick R  et al. (2001) Alpha-Galactosidase A deficiency: Fabry disease. In The Metabolic Bases of Inherited Disease, edn 8, 3733\u20133774 (Eds Scriver C  et al.) New York: McGraw-Hill"},{"key":"BFncpneph0806_CR2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","volume":"30","author":"CM Eng","year":"2007","unstructured":"Eng CM  et al. (2007) Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 30: 184\u2013192","journal-title":"J Inherit Metab Dis"},{"key":"BFncpneph0806_CR3","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","volume":"34","author":"A Mehta","year":"2004","unstructured":"Mehta A  et al. (2004) Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 34: 236\u2013242","journal-title":"Eur J Clin Invest"},{"key":"BFncpneph0806_CR4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/GIM.0b013e31802d8321","volume":"9","author":"RY Wang","year":"2007","unstructured":"Wang RY  et al. (2007) Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med 9: 34\u201345","journal-title":"Genet Med"},{"key":"BFncpneph0806_CR5","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","volume":"93","author":"WR Wilcox","year":"2008","unstructured":"Wilcox WR  et al. (2008) Females with X-linked Fabry disease frequently have significant organ involvement. Mol Genet Metab 93: 112\u2013128","journal-title":"Mol Genet Metab"},{"key":"BFncpneph0806_CR6","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","volume":"81","author":"MH Branton","year":"2002","unstructured":"Branton MH  et al. (2002) Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 81: 122\u2013138","journal-title":"Medicine (Baltimore)"},{"key":"BFncpneph0806_CR7","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","volume":"68","author":"CM Eng","year":"2001","unstructured":"Eng CM  et al. (2001) A phase 1\/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68: 711\u2013722","journal-title":"Am J Hum Genet"},{"key":"BFncpneph0806_CR8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","volume":"75","author":"WR Wilcox","year":"2004","unstructured":"Wilcox WR  et al. (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75: 65\u201374","journal-title":"Am J Hum Genet"},{"key":"BFncpneph0806_CR9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","volume":"146","author":"M Banikazemi","year":"2007","unstructured":"Banikazemi M  et al. (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146: 77\u201386","journal-title":"Ann Intern Med"},{"key":"BFncpneph0806_CR10","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","volume":"18","author":"D Germain","year":"2007","unstructured":"Germain D  et al. (2007) Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18: 1547\u20131557","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0806_CR11","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1517\/14712598.4.7.1167","volume":"4","author":"RJ Desnick","year":"2004","unstructured":"Desnick RJ (2004) Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval. Expert Opin Biol Ther 4: 1167\u20131176","journal-title":"Expert Opin Biol Ther"},{"key":"BFncpneph0806_CR12","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R  et al. (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285: 2743\u20132749","journal-title":"JAMA"},{"key":"BFncpneph0806_CR13","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","volume":"21","author":"R Schiffmann","year":"2006","unstructured":"Schiffmann R  et al. (2006) Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 21: 345\u2013354","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpneph0806_CR14","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1681\/ASN.2006111263","volume":"18","author":"R Schiffmann","year":"2007","unstructured":"Schiffmann R  et al. (2007) Weekly enzyme replacement therapy may slow decline of renal function in Fabry patients who are on long-term biweekly dosing. J Am Soc Nephrol 18: 1576\u20131583","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0806_CR15","doi-asserted-by":"crossref","unstructured":"Ortiz A  et al. (2008) Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant [10.1093\/ndt\/gfm848]","DOI":"10.1093\/ndt\/gfm848"},{"key":"BFncpneph0806_CR16","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1126\/science.172.3979.174","volume":"172","author":"RO Brady","year":"1971","unstructured":"Brady RO  et al. (1971) Fabry's disease: antenatal detection. Science 172: 174\u2013175","journal-title":"Science"},{"key":"BFncpneph0806_CR17","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s10545-006-0196-0","volume":"29","author":"AC Vedder","year":"2006","unstructured":"Vedder AC  et al. (2006) Manifestations of Fabry disease in placental tissue. J Inherit Metab Dis 29: 106\u2013111","journal-title":"J Inherit Metab Dis"},{"key":"BFncpneph0806_CR18","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1523-1755.2004.00846.x","volume":"66","author":"M Ries","year":"2004","unstructured":"Ries M  et al. (2004) Parapelvic kidney cysts: a distinguishing feature with high prevalence in Fabry disease. Kidney Int 66: 978\u2013982","journal-title":"Kidney Int"},{"key":"BFncpneph0806_CR19","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00431-003-1299-3","volume":"162","author":"M Ries","year":"2003","unstructured":"Ries M  et al. (2003) The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Eur J Pediatr 162: 767\u2013772","journal-title":"Eur J Pediatr"},{"key":"BFncpneph0806_CR20","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1542\/peds.2004-1678","volume":"115","author":"M Ries","year":"2005","unstructured":"Ries M  et al. (2005) Pediatric Fabry disease. Pediatrics 115: e344\u2013e355","journal-title":"Pediatrics"},{"key":"BFncpneph0806_CR21","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/ki.1978.32","volume":"13","author":"MC Gubler","year":"1978","unstructured":"Gubler MC  et al. (1978) Early renal changes in hemizygous and heterozygous patients with Fabry's disease. Kidney Int 13: 223\u2013235","journal-title":"Kidney Int"},{"issue":"Suppl 2","key":"BFncpneph0806_CR22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1023\/A:1012447102358","volume":"24","author":"KD MacDermot","year":"2001","unstructured":"MacDermot KD  et al. (2001) Natural history of Fabry disease in affected males and obligate carrier females. J Inherit Metab Dis 24 (Suppl 2): 13\u201314","journal-title":"J Inherit Metab Dis"},{"key":"BFncpneph0806_CR23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/jmg.2005.036327","volume":"43","author":"PB Deegan","year":"2006","unstructured":"Deegan PB  et al. (2006) Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 43: 347\u2013352","journal-title":"J Med Genet"},{"issue":"Suppl 7","key":"BFncpneph0806_CR24","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ndt\/11.supp7.4","volume":"11","author":"D Tsakiris","year":"1996","unstructured":"Tsakiris D  et al. (1996) Report on management of renal failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry. Nephrol Dial Transplant 11 (Suppl 7): 4\u201320","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpneph0806_CR25","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","volume":"138","author":"RJ Desnick","year":"2003","unstructured":"Desnick RJ  et al. (2003) Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138: 338\u2013346","journal-title":"Ann Intern Med"},{"key":"BFncpneph0806_CR26","unstructured":"Hughes DA  et al. (online 1 August 2005) Guidelines for the diagnosis and management of Anderson\u2013Fabry Disease [\n                    http:\/\/www.dh.gov.uk\/en\/Publicationsandstatistics\/Publications\/Publications\u00a0PolicyAndGuidance\/DH_4118404\n                    \n                  ] (accessed 23 October 2007)"},{"key":"BFncpneph0806_CR27","unstructured":"Clarke LA  et al. (online November 2005) Fabry Disease: recommendations for diagnosis, management, and enzyme replacement therapy in Canada [\n                    http:\/\/www.garrod.ca\/data\/attachments\/CanadianFabryGuidelinesNov05.pdf\n                    \n                  ] (accessed 23 October 2007)"},{"key":"BFncpneph0806_CR28","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","volume":"8","author":"CM Eng","year":"2006","unstructured":"Eng CM  et al. (2006) Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 8: 539\u2013548","journal-title":"Genet Med"},{"key":"BFncpneph0806_CR29","unstructured":"Fabry Registry (online 2007) Patient Monitoring [\n                    https:\/\/www.lsdregistry.net\/fabryregistry\/hcp\/partic\/freg_hc_p_monitor.asp\n                    \n                  ] (accessed 23 October 2007)"},{"key":"BFncpneph0806_CR30","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMra054415","volume":"354","author":"LA Stevens","year":"2006","unstructured":"Stevens LA  et al. (2006) Assessing kidney function\u2013measured and estimated glomerular filtration rate. N Engl J Med 354: 2473\u20132483","journal-title":"N Engl J Med"},{"key":"BFncpneph0806_CR31","unstructured":"National Kidney Foundation (2002) K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39 (Suppl 1): S1\u2013S266"},{"key":"BFncpneph0806_CR32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/08035320510028067","volume":"94","author":"J Kleinert","year":"2005","unstructured":"Kleinert J  et al. (2005) Measurement of renal function in patients with Fabry disease. Acta Paediatr Suppl 94: 19\u201323","journal-title":"Acta Paediatr Suppl"},{"issue":"Suppl 2","key":"BFncpneph0806_CR33","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1097\/01.ASN.0000016684.07368.75","volume":"13","author":"J Alroy","year":"2002","unstructured":"Alroy J  et al. (2002) Renal pathology in Fabry disease. J Am Soc Nephrol 13 (Suppl 2): S134\u2013S138","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0806_CR34","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/modpathol.3800344","volume":"18","author":"D Albay","year":"2005","unstructured":"Albay D  et al. (2005) Chloroquine-induced lipidosis mimicking Fabry disease. Mod Pathol 18: 733\u2013738","journal-title":"Mod Pathol"},{"key":"BFncpneph0806_CR35","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/modpathol.3800634","volume":"19","author":"EG Fischer","year":"2006","unstructured":"Fischer EG  et al. (2006) Fabry disease: a morphologic study of 11 cases. Mod Pathol 19: 1295\u20131301","journal-title":"Mod Pathol"},{"key":"BFncpneph0806_CR36","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","volume":"65","author":"D de Zeeuw","year":"2004","unstructured":"de Zeeuw D  et al. (2004) Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 65: 2309\u20132320","journal-title":"Kidney Int"},{"key":"BFncpneph0806_CR37","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1681\/ASN.2006101081","volume":"18","author":"DM Kent","year":"2007","unstructured":"Kent DM  et al. (2007) Progression risk, urinary protein excretion, and treatment effects of Angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol 18: 1959\u20131965","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0806_CR38","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000101958","volume":"27","author":"BF Palmer","year":"2007","unstructured":"Palmer BF (2007) Proteinuria as a therapeutic target in patients with chronic kidney disease. Am J Nephrol 27: 287\u2013293","journal-title":"Am J Nephrol"},{"key":"BFncpneph0806_CR39","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","volume":"62","author":"BL Thurberg","year":"2002","unstructured":"Thurberg BL  et al. (2002) Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62: 1933\u20131946","journal-title":"Kidney Int"},{"key":"BFncpneph0806_CR40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM  et al. (2001) Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med 345: 9\u201316","journal-title":"N Engl J Med"},{"key":"BFncpneph0806_CR41","first-page":"77","volume":"66","author":"A Schwarting","year":"2006","unstructured":"Schwarting A  et al. (2006) Enzyme replacement therapy and renal function in 201 patients with Fabry disease. Clin Nephrol 66: 77\u201384","journal-title":"Clin Nephrol"},{"key":"BFncpneph0806_CR42","unstructured":"ClinicalTrials.gov (online April 2007) Canadian Fabry Disease Initiative (CFDI) Enzyme Replacement Therapy (ERT) Study (NCT00455104) [\n                    http:\/\/clinicaltrials.gov\/ct\/show\/NCT00455104?order=2term=NCT00446862&\u00a0submit=Search\n                    \n                  ] (accessed 23 October 2007)"},{"key":"BFncpneph0806_CR43","doi-asserted-by":"crossref","first-page":"e598","DOI":"10.1371\/journal.pone.0000598","volume":"2","author":"AC Vedder","year":"2007","unstructured":"Vedder AC  et al. (2007) Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg\/kg. PLoS ONE 2: e598","journal-title":"PLoS ONE"},{"key":"BFncpneph0806_CR44","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.ackd.2006.01.013","volume":"13","author":"DG Warnock","year":"2006","unstructured":"Warnock DG and West ML (2006) Diagnosis and management of kidney involvement in Fabry disease. Adv Chronic Kidney Dis 13: 138\u2013147","journal-title":"Adv Chronic Kidney Dis"},{"key":"BFncpneph0806_CR45","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00041552-200503000-00002","volume":"14","author":"DG Warnock","year":"2005","unstructured":"Warnock DG (2005) Fabry disease: diagnosis and management, with emphasis on the renal manifestations. Curr Opin Nephrol Hypertens 14: 87\u201395","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"BFncpneph0806_CR46","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2362.2004.01424.x","volume":"34","author":"M Beck","year":"2004","unstructured":"Beck M  et al. (2004) Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 34: 838\u2013844","journal-title":"Eur J Clin Invest"},{"key":"BFncpneph0806_CR47","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1681\/ASN.2007030312","volume":"18","author":"DG Warnock","year":"2007","unstructured":"Warnock DG (2007) Enzyme replacement therapy and Fabry kidney disease: quo vadis? J Am Soc Nephrol 18: 1368\u20131370","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0806_CR48","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","volume":"289","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV  et al. (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289: 2560\u20132572","journal-title":"JAMA"},{"key":"BFncpneph0806_CR49","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.amjhyper.2006.01.011","volume":"19","author":"J Kleinert","year":"2006","unstructured":"Kleinert J  et al. (2006) Prevalence of uncontrolled hypertension in patients with Fabry disease. Am J Hypertens 19: 782\u2013787","journal-title":"Am J Hypertens"},{"key":"BFncpneph0806_CR50","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1681\/ASN.2006121400","volume":"18","author":"H Tahir","year":"2007","unstructured":"Tahir H  et al. (2007) Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol 18: 2609\u20132617","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0806_CR51","unstructured":"ClinicalTrials.gov (online 10 April 2007) The Fabrazyme\u00ae and Arbs and ACE Inhibitor Treatment (FAACET) Study (NCT00446862) [\n                    http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00446862?order=1\n                    \n                  ] (accessed 23 October 2007)"},{"key":"BFncpneph0806_CR52","unstructured":"Tondel C  et al: Glomerular and vascular changes are prominent in renal biopsies in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis, in press"},{"key":"BFncpneph0806_CR53","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/sj.ki.5000208","volume":"69","author":"F Breunig","year":"2006","unstructured":"Breunig F  et al. (2006) Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int 69: 1216\u20131221","journal-title":"Kidney Int"},{"key":"BFncpneph0806_CR54","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1097\/00007890-200006150-00020","volume":"69","author":"A Ojo","year":"2000","unstructured":"Ojo A  et al. (2000) Excellent outcome of renal transplantation in patients with Fabry's disease. Transplantation 69: 2337\u20132339","journal-title":"Transplantation"},{"key":"BFncpneph0806_CR55","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/j.1523-1755.2004.00514.x","volume":"65","author":"R Mignani","year":"2004","unstructured":"Mignani R  et al. (2004) Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study. Kidney Int 65: 1381\u20131385","journal-title":"Kidney Int"},{"key":"BFncpneph0806_CR56","doi-asserted-by":"crossref","first-page":"142","DOI":"10.7326\/0003-4819-146-2-200701160-00147","volume":"146","author":"R Schiffmann","year":"2007","unstructured":"Schiffmann R (2007) Enzyme replacement in Fabry disease: the essence is in the kidney. Ann Intern Med 146: 142\u2013144","journal-title":"Ann Intern Med"},{"key":"BFncpneph0806_CR57","first-page":"626A","volume":"17","author":"A Fogo","year":"2006","unstructured":"Fogo A  et al. (2006) Developing a chronicity index for kidney involvement in Fabry disease; report of the International Fabry kidney biopsy working group [abstract]. J Am Soc Nephrol 17: 626A","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0806_CR58","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/S0149-2918(07)80121-4","volume":"29","author":"JP Oliveira","year":"2007","unstructured":"Oliveira JP (2007) Staging of Fabry disease using renal biopsies. Clin Ther 29: S15\u2013S16","journal-title":"Clin Ther"}],"container-title":["Nature Clinical Practice Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpneph0806.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpneph0806","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpneph0806.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:21:20Z","timestamp":1684441280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpneph0806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,22]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["BFncpneph0806"],"URL":"https:\/\/doi.org\/10.1038\/ncpneph0806","relation":{},"ISSN":["1745-8323","1745-8331"],"issn-type":[{"value":"1745-8323","type":"print"},{"value":"1745-8331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,22]]}}}